2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis
Abstract Objectives To update the recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis issued in 2003 by the French National Authority for Health (HAS). This update was performed under the aegis of the Bone Section of the French Society for Rheumatology (SFR) and Os...
Saved in:
| Published in | Joint, bone, spine : revue du rhumatisme Vol. 81; no. 6; pp. 493 - 501 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
France
Elsevier SAS
01.12.2014
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Abstract Objectives To update the recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis issued in 2003 by the French National Authority for Health (HAS). This update was performed under the aegis of the Bone Section of the French Society for Rheumatology (SFR) and Osteoporosis Research and Information Group (GRIO), in collaboration with four French learned societies (primary-care, gastroenterology, internal medicine, and nephrology). Methods A task force composed of members of the medical specialties involved in managing patients with glucocorticoid-induced osteoporosis conducted a systematic literature review according to the method developed by the HAS then used the results to develop updated recommendations. Results These recommendations are intended for all physicians involved in the management of patients who are scheduled to start, or are taking, long-term glucocorticoid therapy (≥ 3 months) in any dose and for any reason. In postmenopausal women and men older than 50 years of age, treatment is warranted in the presence of any of the following risk factors for fracture: history of bone frailty fracture after 50 years of age, bone mineral density T-score ≤ −2.5 at one or more sites, age ≥ 70 years, and dosage ≥ 7.5 mg/d prednisone-equivalent for longer than 3 months. Bisphosphonates can be used in all these situations; teriparatide can be given as first-line therapy in patients at high fracture risk but is reimbursed by the French statutory health insurance system only in patients having two or more prevalent vertebral fractures. The fracture risk is lower in nonmenopausal women and in men younger than 50 years of age, in whom treatment decisions should rest on a case-by-case evaluation. Conclusion These recommendations are intended to clarify the pharmacological management of glucocorticoid-induced osteoporosis. |
|---|---|
| AbstractList | Abstract Objectives To update the recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis issued in 2003 by the French National Authority for Health (HAS). This update was performed under the aegis of the Bone Section of the French Society for Rheumatology (SFR) and Osteoporosis Research and Information Group (GRIO), in collaboration with four French learned societies (primary-care, gastroenterology, internal medicine, and nephrology). Methods A task force composed of members of the medical specialties involved in managing patients with glucocorticoid-induced osteoporosis conducted a systematic literature review according to the method developed by the HAS then used the results to develop updated recommendations. Results These recommendations are intended for all physicians involved in the management of patients who are scheduled to start, or are taking, long-term glucocorticoid therapy (≥ 3 months) in any dose and for any reason. In postmenopausal women and men older than 50 years of age, treatment is warranted in the presence of any of the following risk factors for fracture: history of bone frailty fracture after 50 years of age, bone mineral density T-score ≤ −2.5 at one or more sites, age ≥ 70 years, and dosage ≥ 7.5 mg/d prednisone-equivalent for longer than 3 months. Bisphosphonates can be used in all these situations; teriparatide can be given as first-line therapy in patients at high fracture risk but is reimbursed by the French statutory health insurance system only in patients having two or more prevalent vertebral fractures. The fracture risk is lower in nonmenopausal women and in men younger than 50 years of age, in whom treatment decisions should rest on a case-by-case evaluation. Conclusion These recommendations are intended to clarify the pharmacological management of glucocorticoid-induced osteoporosis. OBJECTIVESTo update the recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis issued in 2003 by the French National Authority for Health (HAS). This update was performed under the aegis of the Bone Section of the French Society for Rheumatology (SFR) and Osteoporosis Research and Information Group (GRIO), in collaboration with four French learned societies (primary-care, gastroenterology, internal medicine, and nephrology). METHODSA task force composed of members of the medical specialties involved in managing patients with glucocorticoid-induced osteoporosis conducted a systematic literature review according to the method developed by the HAS then used the results to develop updated recommendations. RESULTSThese recommendations are intended for all physicians involved in the management of patients who are scheduled to start, or are taking, long-term glucocorticoid therapy (≥ 3 months) in any dose and for any reason. In postmenopausal women and men older than 50 years of age, treatment is warranted in the presence of any of the following risk factors for fracture: history of bone frailty fracture after 50 years of age, bone mineral density T-score ≤ −2.5 at one or more sites, age ≥ 70 years, and dosage ≥ 7.5 mg/d prednisone-equivalent for longer than 3 months. Bisphosphonates can be used in all these situations; teriparatide can be given as first-line therapy in patients at high fracture risk but is reimbursed by the French statutory health insurance system only in patients having two or more prevalent vertebral fractures. The fracture risk is lower in non-menopausal women and in men younger than 50 years of age,in whom treatment decisions should rest on a case-by-case evaluation. CONCLUSIONThese recommendations are intended to clarify the pharmacological management of glucocorticoid-induced osteoporosis. To update the recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis issued in 2003 by the French National Authority for Health (HAS). This update was performed under the aegis of the Bone Section of the French Society for Rheumatology (SFR) and Osteoporosis Research and Information Group (GRIO), in collaboration with four French learned societies (primary-care, gastroenterology, internal medicine, and nephrology). A task force composed of members of the medical specialties involved in managing patients with glucocorticoid-induced osteoporosis conducted a systematic literature review according to the method developed by the HAS then used the results to develop updated recommendations. These recommendations are intended for all physicians involved in the management of patients who are scheduled to start, or are taking, long-term glucocorticoid therapy (≥3 months) in any dose and for any reason. In postmenopausal women and men older than 50 years of age, treatment is warranted in the presence of any of the following risk factors for fracture: history of bone frailty fracture after 50 years of age, bone mineral density T-score ≤−2.5 at one or more sites, age ≥70 years, and dosage ≥7.5mg/d prednisone-equivalent for longer than 3 months. Bisphosphonates can be used in all these situations; teriparatide can be given as first-line therapy in patients at high fracture risk but is reimbursed by the French statutory health insurance system only in patients having two or more prevalent vertebral fractures. The fracture risk is lower in nonmenopausal women and in men younger than 50 years of age, in whom treatment decisions should rest on a case-by-case evaluation. These recommendations are intended to clarify the pharmacological management of glucocorticoid-induced osteoporosis. To update the recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis issued in 2003 by the French National Authority for Health (HAS). This update was performed under the aegis of the Bone Section of the French Society for Rheumatology (SFR) and Osteoporosis Research and Information Group (GRIO), in collaboration with four French learned societies (primary-care, gastroenterology, internal medicine, and nephrology). A task force composed of members of the medical specialties involved in managing patients with glucocorticoid-induced osteoporosis conducted a systematic literature review according to the method developed by the HAS then used the results to develop updated recommendations. These recommendations are intended for all physicians involved in the management of patients who are scheduled to start, or are taking, long-term glucocorticoid therapy (≥ 3 months) in any dose and for any reason. In postmenopausal women and men older than 50 years of age, treatment is warranted in the presence of any of the following risk factors for fracture: history of bone frailty fracture after 50 years of age, bone mineral density T-score ≤ −2.5 at one or more sites, age ≥ 70 years, and dosage ≥ 7.5 mg/d prednisone-equivalent for longer than 3 months. Bisphosphonates can be used in all these situations; teriparatide can be given as first-line therapy in patients at high fracture risk but is reimbursed by the French statutory health insurance system only in patients having two or more prevalent vertebral fractures. The fracture risk is lower in non-menopausal women and in men younger than 50 years of age,in whom treatment decisions should rest on a case-by-case evaluation. These recommendations are intended to clarify the pharmacological management of glucocorticoid-induced osteoporosis. Objectives: To update the recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis issued in 2003 by the French National Authority for Health (HAS). This update was performed under the aegis of the Bone Section of the French Society for Rheumatology (SFR) and Osteoporosis Research and Information Group (GRIO), in collaboration with four French learned societies (primary-care, gastroenterology, internal medicine, and nephrology). Methods: A task force composed of members of the medical specialties involved in managing patients with glucocorticoid-induced osteoporosis conducted a systematic literature review according to the method developed by the HAS then used the results to develop updated recommendations. Results: These recommendations are intended for all physicians involved in the management of patients who are scheduled to start, or are taking, long-term glucocorticoid therapy ( greater than or equal to 3 months) in any dose and for any reason. In postmenopausal women and men older than 50 years of age, treatment is warranted in the presence of any of the following risk factors for fracture: history of bone frailty fracture after 50 years of age, bone mineral density T-score less than or equal to -2.5 at one or more sites, age greater than or equal to 70 years, and dosage greater than or equal to 7.5 mg/d prednisone-equivalent for longer than 3 months. Bisphosphonates can be used in all these situations; teriparatide can be given as first-line therapy in patients at high fracture risk but is reimbursed by the French statutory health insurance system only in patients having two or more prevalent vertebral fractures. The fracture risk is lower in nonmenopausal women and in men younger than 50 years of age, in whom treatment decisions should rest on a case-by-case evaluation. Conclusion: These recommendations are intended to clarify the pharmacological management of glucocorticoid-induced osteoporosis. |
| Author | Fardet, Laurence Laroche, Michel Lespessailles, Eric Thomas, Thierry Debiais, Françoise Guggenbuhl, Pascal Cortet, Bernard Marcelli, Christian Abitbol, Vered Buchon, Daniel Bacchetta, Justine Legrand, Erik Briot, Karine Roux, Christian Weryha, Georges |
| Author_xml | – sequence: 1 fullname: Briot, Karine – sequence: 2 fullname: Cortet, Bernard – sequence: 3 fullname: Roux, Christian – sequence: 4 fullname: Fardet, Laurence – sequence: 5 fullname: Abitbol, Vered – sequence: 6 fullname: Bacchetta, Justine – sequence: 7 fullname: Buchon, Daniel – sequence: 8 fullname: Debiais, Françoise – sequence: 9 fullname: Guggenbuhl, Pascal – sequence: 10 fullname: Laroche, Michel – sequence: 11 fullname: Legrand, Erik – sequence: 12 fullname: Lespessailles, Eric – sequence: 13 fullname: Marcelli, Christian – sequence: 14 fullname: Weryha, Georges – sequence: 15 fullname: Thomas, Thierry |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25455041$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUktv1jAQtFAr-oB_gFCOXPLhRxzbFyRUlYdUiQOt1Jvl2BtwSOxgO5X673H0FQ5c4GR7PLOrndkLdBJiAIReEXwgmPRvp8M05NWHA8Wkq9ABY_IMnRMhZCso707qnSrRMqLuz9BFzhPGmFHeP0dn9Ztz3JFzBLu62VZnCjRxbBLYuCwQ6tvHkJsYmvIdmjXBA4QdakxwTUlgSmWVXfJt3my0MRVvo3etD26z4JqYC8Q1pph9foFORzNnePl0XqK7D9e3V5_amy8fP1-9v2ktJ31pmRyEGgcGSnEnJZdSOoFt7wxWXBnBuOpHJdVAZWdHITgeORv7kTnJmRsYu0RvjnXXFH9ukItefLYwzyZA3LImvWBMcsXFf1A57Uj1a6d2R6qtw-QEo16TX0x61ATrPQs96WMWendzR2sWVfb6qcM2LOD-iH6bXwnvjgSoljx4SDpbD6Ga52sMRbvo_9Xh7wJ29sFbM_-AR8hT3FKodmuiM9VYf933YV8H0mFMKe7ZL6y1s18 |
| CitedBy_id | crossref_primary_10_1111_nyas_14208 crossref_primary_10_1016_j_imr_2021_100803 crossref_primary_10_1155_2021_5515653 crossref_primary_10_1016_j_rcreue_2017_03_005 crossref_primary_10_1016_j_jbspin_2023_105599 crossref_primary_10_1016_j_rhum_2024_06_004 crossref_primary_10_1016_S1286_935X_22_46490_2 crossref_primary_10_1007_s00223_019_00607_z crossref_primary_10_1111_os_12296 crossref_primary_10_2106_JBJS_RVW_18_00052 crossref_primary_10_1007_s00198_019_04906_x crossref_primary_10_3803_EnM_2021_1021 crossref_primary_10_1080_14397595_2020_1812835 crossref_primary_10_3899_jrheum_180889 crossref_primary_10_3904_kjm_2017_92_2_142 crossref_primary_10_3109_13697137_2015_1103615 crossref_primary_10_1007_s11657_021_00902_z crossref_primary_10_1136_annrheumdis_2015_208916 crossref_primary_10_1016_j_rmr_2021_08_002 crossref_primary_10_1007_s00774_022_01325_7 crossref_primary_10_1186_s13023_020_01621_3 crossref_primary_10_11005_jbm_2020_27_4_247 crossref_primary_10_1007_s00198_020_05568_w crossref_primary_10_1007_s00296_018_4106_1 crossref_primary_10_1007_s12020_016_1146_8 crossref_primary_10_1016_j_revmed_2021_10_300 crossref_primary_10_1016_j_lpmfor_2020_08_001 crossref_primary_10_1016_j_rcreu_2016_11_003 crossref_primary_10_3390_cells11030536 crossref_primary_10_1055_s_0042_1758779 crossref_primary_10_1136_rmdopen_2014_000014 crossref_primary_10_22141_2224_1507_9_4_2019_191923 crossref_primary_10_1016_j_jbspin_2015_11_007 crossref_primary_10_1016_j_ejbt_2021_04_002 crossref_primary_10_1016_j_lpm_2014_07_028 crossref_primary_10_1016_j_lpm_2019_06_002 crossref_primary_10_1016_S1634_7358_24_48829_3 crossref_primary_10_1007_s00198_021_06265_y crossref_primary_10_1007_s10787_018_0541_6 crossref_primary_10_1002_acr_23429 crossref_primary_10_11005_jbm_2018_25_4_195 crossref_primary_10_1016_j_clinthera_2017_01_008 crossref_primary_10_1016_S1634_7358_18_41329_0 crossref_primary_10_1016_j_yaoo_2017_03_014 crossref_primary_10_1007_s40520_021_01823_0 crossref_primary_10_1097_MD_0000000000003990 crossref_primary_10_4078_jrd_2018_25_4_263 crossref_primary_10_1016_j_jbspin_2024_105730 crossref_primary_10_1007_s00296_019_04407_4 crossref_primary_10_1016_j_monrhu_2016_05_003 crossref_primary_10_1016_j_steroids_2024_109440 crossref_primary_10_1097_IIO_0000000000000470 crossref_primary_10_1136_rmdopen_2016_000249 crossref_primary_10_1016_j_neurol_2020_01_362 crossref_primary_10_1016_j_bone_2015_10_016 crossref_primary_10_1016_j_revmed_2020_04_011 crossref_primary_10_3389_fendo_2022_908727 crossref_primary_10_1016_S1636_5410_23_47692_1 crossref_primary_10_1016_j_jbspin_2022_105373 crossref_primary_10_1016_j_rhum_2016_07_004 crossref_primary_10_1016_j_revmed_2018_10_388 crossref_primary_10_1155_2015_729451 crossref_primary_10_1016_j_monrhu_2019_02_006 crossref_primary_10_1016_j_rhum_2021_10_492 crossref_primary_10_1007_s00774_021_01236_z crossref_primary_10_1016_j_jbspin_2023_105549 crossref_primary_10_1016_j_jbspin_2018_03_016 crossref_primary_10_1016_S1286_935X_22_47184_X crossref_primary_10_1016_S1762_827X_23_47629_8 crossref_primary_10_3390_pharmacy12030080 crossref_primary_10_1016_S1636_5410_19_42596_8 crossref_primary_10_1136_bmjopen_2017_015905 crossref_primary_10_1136_lupus_2015_000098 crossref_primary_10_1186_s12913_019_4052_y crossref_primary_10_1016_j_berh_2022_101793 crossref_primary_10_1016_S1636_5410_18_41297_4 crossref_primary_10_1016_j_rhum_2021_02_024 crossref_primary_10_1016_j_rhum_2019_08_012 crossref_primary_10_1038_s41574_020_0341_0 crossref_primary_10_1016_j_ando_2018_04_016 crossref_primary_10_1016_j_rhum_2023_10_004 crossref_primary_10_3390_medicina58020324 crossref_primary_10_1016_j_rdc_2015_08_005 crossref_primary_10_1093_rheumatology_keae142 crossref_primary_10_1007_s40520_022_02261_2 crossref_primary_10_1097_MD_0000000000024559 crossref_primary_10_1177_0960327116649674 crossref_primary_10_1007_s11940_017_0440_y |
| Cites_doi | 10.1007/s00198-007-0394-0 10.1136/bmj.39440.525752.BE 10.1002/jbmr.176 10.1007/s002230001146 10.1359/jbmr.2000.15.6.993 10.1136/bmj.313.7053.344 10.1007/s00198-005-2017-y 10.1002/jbmr.1489 10.1007/s00198-011-1584-3 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W 10.1002/art.11283 10.1210/jc.2008-1578 10.1136/ard.2005.044198 10.1056/NEJMoa071408 10.1007/s00198-007-0543-5 10.1359/JBMR.040134 10.1111/j.1365-2796.2006.01754.x 10.1002/art.22462 10.1002/art.10619 10.1007/s00198-013-2321-x 10.1016/j.bone.2011.10.024 10.1007/s00198-007-0550-6 10.1002/art.24879 10.1007/s00198-007-0345-9 10.1359/jbmr.2000.15.6.1006 10.1016/j.bone.2010.05.019 10.3310/hta11070 10.1007/s001980200108 10.1002/art.22117 10.1136/bmj.f6234 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K 10.1002/acr.20295 10.1007/s00198-013-2352-3 10.1002/art.10613 10.1016/j.jocd.2011.05.014 10.1007/s00198-012-1958-1 10.1093/qjmed/hci029 10.1016/j.lpm.2011.04.001 10.1503/cmaj.090710 10.1007/s002239900351 10.7326/0003-4819-119-10-199311150-00001 10.1210/jc.2011-2036 10.1016/j.ecl.2012.04.004 10.1136/ard.2008.091611 10.1016/j.jbspin.2012.02.014 10.1016/j.berh.2009.09.006 10.1016/j.bone.2011.05.007 10.1016/j.jocd.2007.12.008 10.1210/jcem.83.4.4742 10.1093/rheumatology/ker017 10.1056/NEJM199807303390502 10.1016/j.maturitas.2009.03.006 10.1007/s00198-012-2220-6 10.1016/j.bone.2006.02.005 10.1016/j.bone.2009.06.030 10.1007/s00198-010-1524-7 10.1016/S0140-6736(09)60250-6 10.1136/bmj.c3691 10.1136/bmj.d2040 10.1001/jama.2010.594 10.1056/NEJMoa1010650 |
| ContentType | Journal Article |
| Copyright | Société française de rhumatologie 2014 Société française de rhumatologie |
| Copyright_xml | – notice: Société française de rhumatologie – notice: 2014 Société française de rhumatologie |
| CorporateAuthor | Bone Section of the French Society for Rheumatology (SFR) and Osteoporosis Research and Information Group (GRIO) |
| CorporateAuthor_xml | – name: Bone Section of the French Society for Rheumatology (SFR) and Osteoporosis Research and Information Group (GRIO) |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 7QP |
| DOI | 10.1016/j.jbspin.2014.10.001 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic Calcium & Calcified Tissue Abstracts |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic Calcium & Calcified Tissue Abstracts |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Calcium & Calcified Tissue Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1778-7254 |
| EndPage | 501 |
| ExternalDocumentID | 10_1016_j_jbspin_2014_10_001 25455041 S1297319X14002206 1_s2_0_S1297319X14002206 |
| Genre | Journal Article Practice Guideline |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1B1 1P~ 1~. 1~5 29J 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ AABNK AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAWTL AAXKI AAXUO ABBQC ABFNM ABJNI ABMAC ABMZM ABXDB ACDAQ ACGFS ACRLP ADBBV ADEZE ADMUD AEBSH AEKER AENEX AEVXI AFCTW AFJKZ AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 EBS EFJIC EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W KOM LN9 M41 MO0 N9A O-L O9- OAUVE OI0 OV- OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SDF SDG SEM SES SEW SPCBC SSH SSZ T5K UHS Z5R ~G- CGR CUY CVF ECM EIF NPM AAYXX ACRPL ADNMO CITATION 7X8 7QP |
| ID | FETCH-LOGICAL-c516t-38b79fb3e995d885888d70c6da0959a73596f989b284cf7750f53f6f3d853db33 |
| IEDL.DBID | AIKHN |
| ISSN | 1297-319X |
| IngestDate | Fri Oct 25 06:24:44 EDT 2024 Thu Oct 24 23:46:41 EDT 2024 Fri Dec 06 02:45:56 EST 2024 Sat Sep 28 08:30:42 EDT 2024 Tue Oct 08 04:54:21 EDT 2024 Tue Oct 15 22:56:17 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Recommendations Osteoporosis Fracture Glucocorticoids Bisphosphonates Teriparatide |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c516t-38b79fb3e995d885888d70c6da0959a73596f989b284cf7750f53f6f3d853db33 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Instructional Material/Guideline-2 ObjectType-Feature-3 content type line 23 ObjectType-Feature-2 |
| PMID | 25455041 |
| PQID | 1652413257 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_1673385957 proquest_miscellaneous_1652413257 crossref_primary_10_1016_j_jbspin_2014_10_001 pubmed_primary_25455041 elsevier_sciencedirect_doi_10_1016_j_jbspin_2014_10_001 elsevier_clinicalkeyesjournals_1_s2_0_S1297319X14002206 |
| PublicationCentury | 2000 |
| PublicationDate | 2014-12-01 |
| PublicationDateYYYYMMDD | 2014-12-01 |
| PublicationDate_xml | – month: 12 year: 2014 text: 2014-12-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | France |
| PublicationPlace_xml | – name: France |
| PublicationTitle | Joint, bone, spine : revue du rhumatisme |
| PublicationTitleAlternate | Joint Bone Spine |
| PublicationYear | 2014 |
| Publisher | Elsevier SAS |
| Publisher_xml | – name: Elsevier SAS |
| References | Koetz, Ventz, Diederich (bib0065) 2012; 97 Adachi, Saag, Delmas (bib0185) 2001; 44 Bolland, Avenell, Baron (bib0240) 2010; 341 van Staa, Geusens, Bijlsma (bib0195) 2006; 54 Briot, Legrand, Pouchain (bib0320) 2010; 6 Fardet, Petersen, Nazareth (bib0015) 2011; 50 Kanis, Johnell, Oden (bib0205) 2008; 19 Van Staa, Geusens, Pols (bib0175) 2005; 98 Majumdar, Morin, Lix (bib0140) 2013; 9 Tatsuno, Sugiyama, Suzuki (bib0170) 2009; 94 Saag, Emkey, Schnitzer (bib0180) 1999; 339 Roux, Oriente, Laan (bib0270) 1998; 83 Saag, Zanchetta, Devogelaer (bib0300) 2009; 60 Reid, Hughes, Laan (bib0105) 2000; 15 Roussy, Bessette, Bernatsky (bib0160) 2013; 24 Benhamou, Souberbielle, Cortet (bib0260) 2011; 40 Shane, Burr, Abrahamsen (bib0330) 2013 Weinstein (bib0080) 2010; 46 Reid, Devogelaer, Saag (bib0285) 2009; 373 Laan, van Riel, van de Putte (bib0110) 1993; 119 El-Khoury, Cassou, Charles (bib0230) 2013; 347 Sambrook, Roux, Devogelaer (bib0290) 2012; 50 Pentti, Tuppurainen, Honkanen (bib0245) 2009; 63 Schousboe, Vokes, Broy (bib0220) 2008; 11 Grossman, Gordon, Ranganath (bib0070) 2010; 62 Saag, Shane, Boonen (bib0295) 2007; 357 Kok, Sambrook (bib0025) 2009; 23 Leib, Saag, Adachi (bib0215) 2011; 14 Buckley, Marquez, Hudson (bib0035) 1998; 25 Sanders, Stuart, Williamson (bib0265) 2010; 303 Wibaux, Baudens, Fiorentino-Devulder (bib0060) 2010; S77 Siminoski, Warshawski, Jen (bib0325) 2006; 17 Giusti, Hamdy, Papapoulos (bib0335) 2010; 47 Ghazi, Kolta, Briot (bib0165) 2012; 23 Bolland, Barber, Doughty (bib0235) 2008; 336 Weinstein (bib0090) 2012; 41 Kanis, Stevenson, McCloskey (bib0305) 2007; 11 de Vries, Pouwels, Lammers (bib0150) 2007; 261 Lewis, Calver, Zhu (bib0255) 2011; 26 Walsh, Wong, Pringle (bib0005) 1996; 313 Kim, Schneeweiss, Liu (bib0155) 2012; 27 Adachi, Roux, Pitt (bib0275) 2000; 27 McKenzie, Reynolds, O’Fallon (bib0115) 2000; 27 Lekamwasam, Adachi, Agnusdei (bib0075) 2012; 23 Wijbrandts, Klaasen, Dijkgraaf (bib0125) 2009; 68 Canalis, Mazziotti, Giustina (bib0085) 2007; 18 Ramsey-Goldman (bib0030) 2002; 46 Van Staa, Leufkens, Abenhaim (bib0130) 2000; 15 Brask-Lindemann, Eiken, Eskildsen (bib0055) 2013; 24 Thompson, Modin, Arnaud (bib0190) 1997; 61 Tosteson, Melton, Dawson-Hughes (bib0310) 2008; 19 Schilcher, Michaëlsson, Aspenberg (bib0340) 2011; 364 Solomon, Katz, Jacobs (bib0045) 2002; 46 van Staa, Leufkens, Cooper (bib0095) 2002; 13 Kanis, Johansson, Oden (bib0135) 2004; 19 Homik, Cranney, Shea (bib0315) 2000; 2 Vis, Havaardsholm, Haugeberg (bib0120) 2006; 65 Kanis, Johansson, Oden (bib0210) 2011; 22 Cohen, Levy, Keller (bib0100) 1999; 42 Angeli, Guglielmi, Dovio (bib0145) 2006; 39 Duyvendak, Naunton, Atthobari (bib0050) 2007; 18 Van Staa, Laan, Barton (bib0200) 2003; 48 Wallach, Cohen, Reid (bib0280) 2000; 67 Díez-Pérez, Hooven, Adachi (bib0020) 2011; 49 Briot, Cortet, Thomas (bib0225) 2012; 79 Guzman-Clark, Fang, Sehl (bib0040) 2007; 57 Soucy, Bellamy, Adachi (bib0010) 2000; 27 Bolland, Grey, Avenell (bib0250) 2011; 342 25238949 - Joint Bone Spine. 2014 Dec;81(6):465-8 Giusti (10.1016/j.jbspin.2014.10.001_bib0335) 2010; 47 van Staa (10.1016/j.jbspin.2014.10.001_bib0095) 2002; 13 Ghazi (10.1016/j.jbspin.2014.10.001_bib0165) 2012; 23 Fardet (10.1016/j.jbspin.2014.10.001_bib0015) 2011; 50 Wijbrandts (10.1016/j.jbspin.2014.10.001_bib0125) 2009; 68 de Vries (10.1016/j.jbspin.2014.10.001_bib0150) 2007; 261 Homik (10.1016/j.jbspin.2014.10.001_bib0315) 2000; 2 El-Khoury (10.1016/j.jbspin.2014.10.001_bib0230) 2013; 347 Briot (10.1016/j.jbspin.2014.10.001_bib0225) 2012; 79 Sambrook (10.1016/j.jbspin.2014.10.001_bib0290) 2012; 50 Brask-Lindemann (10.1016/j.jbspin.2014.10.001_bib0055) 2013; 24 Bolland (10.1016/j.jbspin.2014.10.001_bib0250) 2011; 342 Adachi (10.1016/j.jbspin.2014.10.001_bib0185) 2001; 44 Weinstein (10.1016/j.jbspin.2014.10.001_bib0090) 2012; 41 McKenzie (10.1016/j.jbspin.2014.10.001_bib0115) 2000; 27 Grossman (10.1016/j.jbspin.2014.10.001_bib0070) 2010; 62 Bolland (10.1016/j.jbspin.2014.10.001_bib0240) 2010; 341 Lekamwasam (10.1016/j.jbspin.2014.10.001_bib0075) 2012; 23 Leib (10.1016/j.jbspin.2014.10.001_bib0215) 2011; 14 Soucy (10.1016/j.jbspin.2014.10.001_bib0010) 2000; 27 Van Staa (10.1016/j.jbspin.2014.10.001_bib0200) 2003; 48 Pentti (10.1016/j.jbspin.2014.10.001_bib0245) 2009; 63 Saag (10.1016/j.jbspin.2014.10.001_bib0295) 2007; 357 Ramsey-Goldman (10.1016/j.jbspin.2014.10.001_bib0030) 2002; 46 Sanders (10.1016/j.jbspin.2014.10.001_bib0265) 2010; 303 Kanis (10.1016/j.jbspin.2014.10.001_bib0305) 2007; 11 Koetz (10.1016/j.jbspin.2014.10.001_bib0065) 2012; 97 Kanis (10.1016/j.jbspin.2014.10.001_bib0135) 2004; 19 Angeli (10.1016/j.jbspin.2014.10.001_bib0145) 2006; 39 Solomon (10.1016/j.jbspin.2014.10.001_bib0045) 2002; 46 Walsh (10.1016/j.jbspin.2014.10.001_bib0005) 1996; 313 Reid (10.1016/j.jbspin.2014.10.001_bib0105) 2000; 15 Reid (10.1016/j.jbspin.2014.10.001_bib0285) 2009; 373 Van Staa (10.1016/j.jbspin.2014.10.001_bib0130) 2000; 15 Weinstein (10.1016/j.jbspin.2014.10.001_bib0080) 2010; 46 Schilcher (10.1016/j.jbspin.2014.10.001_bib0340) 2011; 364 Kanis (10.1016/j.jbspin.2014.10.001_bib0205) 2008; 19 Siminoski (10.1016/j.jbspin.2014.10.001_bib0325) 2006; 17 Wallach (10.1016/j.jbspin.2014.10.001_bib0280) 2000; 67 Wibaux (10.1016/j.jbspin.2014.10.001_bib0060) 2010; S77 Duyvendak (10.1016/j.jbspin.2014.10.001_bib0050) 2007; 18 Adachi (10.1016/j.jbspin.2014.10.001_bib0275) 2000; 27 Kim (10.1016/j.jbspin.2014.10.001_bib0155) 2012; 27 Saag (10.1016/j.jbspin.2014.10.001_bib0180) 1999; 339 Laan (10.1016/j.jbspin.2014.10.001_bib0110) 1993; 119 Kok (10.1016/j.jbspin.2014.10.001_bib0025) 2009; 23 van Staa (10.1016/j.jbspin.2014.10.001_bib0195) 2006; 54 Vis (10.1016/j.jbspin.2014.10.001_bib0120) 2006; 65 Briot (10.1016/j.jbspin.2014.10.001_bib0320) 2010; 6 Buckley (10.1016/j.jbspin.2014.10.001_bib0035) 1998; 25 Thompson (10.1016/j.jbspin.2014.10.001_bib0190) 1997; 61 Lewis (10.1016/j.jbspin.2014.10.001_bib0255) 2011; 26 Bolland (10.1016/j.jbspin.2014.10.001_bib0235) 2008; 336 Roussy (10.1016/j.jbspin.2014.10.001_bib0160) 2013; 24 Kanis (10.1016/j.jbspin.2014.10.001_bib0210) 2011; 22 Tosteson (10.1016/j.jbspin.2014.10.001_bib0310) 2008; 19 Tatsuno (10.1016/j.jbspin.2014.10.001_bib0170) 2009; 94 Van Staa (10.1016/j.jbspin.2014.10.001_bib0175) 2005; 98 Shane (10.1016/j.jbspin.2014.10.001_bib0330) 2013 Benhamou (10.1016/j.jbspin.2014.10.001_bib0260) 2011; 40 Schousboe (10.1016/j.jbspin.2014.10.001_bib0220) 2008; 11 Roux (10.1016/j.jbspin.2014.10.001_bib0270) 1998; 83 Saag (10.1016/j.jbspin.2014.10.001_bib0300) 2009; 60 Guzman-Clark (10.1016/j.jbspin.2014.10.001_bib0040) 2007; 57 Canalis (10.1016/j.jbspin.2014.10.001_bib0085) 2007; 18 Díez-Pérez (10.1016/j.jbspin.2014.10.001_bib0020) 2011; 49 Cohen (10.1016/j.jbspin.2014.10.001_bib0100) 1999; 42 Majumdar (10.1016/j.jbspin.2014.10.001_bib0140) 2013; 9 |
| References_xml | – volume: 313 start-page: 344 year: 1996 end-page: 346 ident: bib0005 article-title: Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross-sectional study publication-title: BMJ contributor: fullname: Pringle – volume: 39 start-page: 253 year: 2006 end-page: 259 ident: bib0145 article-title: High prevalence of asymptomatic vertebral fractures in postmenopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study publication-title: Bone contributor: fullname: Dovio – volume: 67 start-page: 277 year: 2000 end-page: 285 ident: bib0280 article-title: Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy publication-title: Calcif Tissue Int contributor: fullname: Reid – volume: 50 start-page: 289 year: 2012 end-page: 295 ident: bib0290 article-title: Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate publication-title: Bone contributor: fullname: Devogelaer – year: 2013 ident: bib0330 article-title: Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research publication-title: J Bone Miner Res contributor: fullname: Abrahamsen – volume: 17 start-page: 290 year: 2006 end-page: 296 ident: bib0325 article-title: The accuracy of historical height loss for the detection of vertebral fractures in postmenopausal women publication-title: Osteoporos Int contributor: fullname: Jen – volume: 98 start-page: 191 year: 2005 end-page: 198 ident: bib0175 article-title: A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids publication-title: QJM contributor: fullname: Pols – volume: 15 start-page: 1006 year: 2000 end-page: 1013 ident: bib0105 article-title: Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study publication-title: J Bone Miner Res contributor: fullname: Laan – volume: 18 start-page: 1319 year: 2007 end-page: 1328 ident: bib0085 article-title: Glucocorticoid-induced osteoporosis: pathophysiology and therapy publication-title: Osteoporos Int contributor: fullname: Giustina – volume: 23 start-page: 2257 year: 2012 end-page: 2276 ident: bib0075 article-title: A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis publication-title: Osteoporos Int contributor: fullname: Agnusdei – volume: 94 start-page: 1671 year: 2009 end-page: 1677 ident: bib0170 article-title: Age dependence of early symptomatic vertebral fracture with high-dose glucocorticoid treatment for collagen vascular diseases publication-title: J Clin Endocrinol Metab contributor: fullname: Suzuki – volume: 27 start-page: 2424 year: 2000 end-page: 2431 ident: bib0275 article-title: A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid-induced bone loss publication-title: J Rheumatol contributor: fullname: Pitt – volume: 18 start-page: 1429 year: 2007 end-page: 1433 ident: bib0050 article-title: Corticosteroid-induced osteoporosis prevention: longitudinal practice patterns in The Netherlands 2001–2005 publication-title: Osteoporos Int contributor: fullname: Atthobari – volume: 47 start-page: 169 year: 2010 end-page: 180 ident: bib0335 article-title: Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies publication-title: Bone contributor: fullname: Papapoulos – volume: 364 start-page: 1728 year: 2011 end-page: 1737 ident: bib0340 article-title: Bisphosphonate use and atypical fractures of the femoral shaft publication-title: N Engl J Med contributor: fullname: Aspenberg – volume: 22 start-page: 809 year: 2011 end-page: 816 ident: bib0210 article-title: Guidance for the adjustment of FRAX publication-title: Osteoporos Int contributor: fullname: Oden – volume: 27 start-page: 1506 year: 2000 end-page: 1512 ident: bib0010 article-title: A Canadian survey on the management of corticosteroid-induced osteoporosis by rheumatologists publication-title: J Rheumatol contributor: fullname: Adachi – volume: 23 start-page: 769 year: 2009 end-page: 779 ident: bib0025 article-title: Secondary osteoporosis in patients with an osteoporotic fracture publication-title: Best Pract Res Clin Rheumatol contributor: fullname: Sambrook – volume: 79 start-page: 304 year: 2012 end-page: 313 ident: bib0225 article-title: 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis publication-title: Joint Bone Spine contributor: fullname: Thomas – volume: 347 start-page: f6234 year: 2013 ident: bib0230 article-title: The effect of fall prevention exercise programmes on fall induced injuries in community dwelling older adults: systematic review and meta-analysis of randomised controlled trials publication-title: BMJ contributor: fullname: Charles – volume: 341 start-page: c3691 year: 2010 ident: bib0240 article-title: Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis publication-title: BMJ contributor: fullname: Baron – volume: 303 start-page: 1815 year: 2010 end-page: 1822 ident: bib0265 article-title: Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial publication-title: JAMA contributor: fullname: Williamson – volume: 119 start-page: 963 year: 1993 end-page: 968 ident: bib0110 article-title: Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study publication-title: Ann Intern Med contributor: fullname: van de Putte – volume: 40 start-page: 673 year: 2011 end-page: 682 ident: bib0260 article-title: La vitamine D chez l’adulte : recommandations du GRIO publication-title: Presse Med contributor: fullname: Cortet – volume: 60 start-page: 3346 year: 2009 end-page: 3355 ident: bib0300 article-title: Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial publication-title: Arthritis Rheum contributor: fullname: Devogelaer – volume: 54 start-page: 3104 year: 2006 end-page: 3112 ident: bib0195 article-title: Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis publication-title: Arthritis Rheum contributor: fullname: Bijlsma – volume: 63 start-page: 73 year: 2009 end-page: 78 ident: bib0245 article-title: Use of calcium supplementation and the risk of coronary heart disease in 52–62-year-old women: the Kuopio Osteoporosis Risk Factor and Prevention Study publication-title: Maturitas contributor: fullname: Honkanen – volume: 357 start-page: 2028 year: 2007 end-page: 2039 ident: bib0295 article-title: Teriparatide or alendronate in glucocorticoid-induced osteoporosis publication-title: N Engl J Med contributor: fullname: Boonen – volume: 50 start-page: 1982 year: 2011 end-page: 1990 ident: bib0015 article-title: Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years publication-title: Rheumatology (Oxford) contributor: fullname: Nazareth – volume: 65 start-page: 1495 year: 2006 end-page: 1499 ident: bib0120 article-title: Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis publication-title: Ann Rheum Dis contributor: fullname: Haugeberg – volume: 13 start-page: 777 year: 2002 end-page: 787 ident: bib0095 article-title: The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis publication-title: Osteoporos Int contributor: fullname: Cooper – volume: 336 start-page: 262 year: 2008 end-page: 266 ident: bib0235 article-title: Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial publication-title: BMJ contributor: fullname: Doughty – volume: 41 start-page: 595 year: 2012 end-page: 611 ident: bib0090 article-title: Glucocorticoid-induced osteoporosis and osteonecrosis publication-title: Endocrinol Metab Clin North Am contributor: fullname: Weinstein – volume: 25 start-page: 2195 year: 1998 end-page: 2202 ident: bib0035 article-title: Variations in physicians’ judgments about corticosteroid-induced osteoporosis by physician specialty publication-title: J Rheumatol contributor: fullname: Hudson – volume: 27 start-page: 2222 year: 2000 end-page: 2226 ident: bib0115 article-title: Decreased bone mineral density during low dose glucocorticoid administration in a randomized, placebo-controlled trial publication-title: J Rheumatol contributor: fullname: O’Fallon – volume: 27 start-page: 789 year: 2012 end-page: 796 ident: bib0155 article-title: Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study publication-title: J Bone Miner Res contributor: fullname: Liu – volume: 15 start-page: 993 year: 2000 end-page: 1000 ident: bib0130 article-title: Use of oral corticosteroids and risk of fractures publication-title: J Bone Miner Res contributor: fullname: Abenhaim – volume: 24 start-page: 1891 year: 2013 end-page: 1897 ident: bib0055 article-title: Time trends for alendronate prescription practices in women with chronic obstructive pulmonary disease and women exposed to systemic glucocorticoids publication-title: Osteoporos Int contributor: fullname: Eskildsen – volume: 2 start-page: CD001347 year: 2000 ident: bib0315 article-title: Bisphosphonates for steroid-induced osteoporosis publication-title: Cochrane Database Syst Rev contributor: fullname: Shea – volume: 97 start-page: 85 year: 2012 end-page: 92 ident: bib0065 article-title: Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy publication-title: J Clin Endocrinol Metab contributor: fullname: Diederich – volume: 49 start-page: 493 year: 2011 end-page: 498 ident: bib0020 article-title: Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW) publication-title: Bone contributor: fullname: Adachi – volume: 57 start-page: 140 year: 2007 end-page: 146 ident: bib0040 article-title: Barriers in the management of glucocorticoid-induced osteoporosis publication-title: Arthritis Rheum contributor: fullname: Sehl – volume: 9 start-page: 2493 year: 2013 end-page: 2498 ident: bib0140 article-title: Influence of recency and duration of glucocorticoid use on bone mineral density and risk of fractures: population-based cohort study publication-title: Osteoporos Int contributor: fullname: Lix – volume: 42 start-page: 2309 year: 1999 end-page: 2318 ident: bib0100 article-title: Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study publication-title: Arthritis Rheum contributor: fullname: Keller – volume: 62 start-page: 1515 year: 2010 end-page: 1526 ident: bib0070 article-title: American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis publication-title: Arthritis Care Res (Hoboken) contributor: fullname: Ranganath – volume: 261 start-page: 170 year: 2007 end-page: 177 ident: bib0150 article-title: Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study publication-title: J Intern Med contributor: fullname: Lammers – volume: 342 start-page: d2040 year: 2011 ident: bib0250 article-title: Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis publication-title: BMJ contributor: fullname: Avenell – volume: 11 start-page: iii year: 2007 end-page: iv ident: bib0305 article-title: Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis publication-title: Health Technol Assess contributor: fullname: McCloskey – volume: 19 start-page: 437 year: 2008 end-page: 447 ident: bib0310 article-title: Cost-effective osteoporosis treatment thresholds: the United States perspective publication-title: Osteoporos Int contributor: fullname: Dawson-Hughes – volume: 24 start-page: 2483 year: 2013 end-page: 2492 ident: bib0160 article-title: Biologic disease-modifying anti-rheumatic drugs and the risk of non-vertebral osteoporotic fractures in patients with rheumatoid arthritis aged 50 years and over publication-title: Osteoporos Int contributor: fullname: Bernatsky – volume: 48 start-page: 3224 year: 2003 end-page: 3229 ident: bib0200 article-title: Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy publication-title: Arthritis Rheum contributor: fullname: Barton – volume: 83 start-page: 1128 year: 1998 end-page: 1133 ident: bib0270 article-title: Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group publication-title: J Clin Endocrinol Metab contributor: fullname: Laan – volume: 44 start-page: 202 year: 2001 end-page: 211 ident: bib0185 article-title: Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial publication-title: Arthritis Rheum contributor: fullname: Delmas – volume: 46 start-page: 3136 year: 2002 end-page: 3142 ident: bib0045 article-title: Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice publication-title: Arthritis Rheum contributor: fullname: Jacobs – volume: 11 start-page: 92 year: 2008 end-page: 108 ident: bib0220 article-title: Vertebral fracture assessment: the 2007 ISCD official positions publication-title: J Clin Densitom contributor: fullname: Broy – volume: S77 start-page: A86 year: 2010 ident: bib0060 article-title: Évolution de la prise en charge de l’ostéoporose cortisonique au sein du réseau rhumatisme inflammatoire chronique du Nord-Pas-de-Calais entre 2007 et 2010 publication-title: Rev Rhum contributor: fullname: Fiorentino-Devulder – volume: 339 start-page: 292 year: 1999 end-page: 299 ident: bib0180 article-title: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis publication-title: N Engl J Med contributor: fullname: Schnitzer – volume: 61 start-page: 377 year: 1997 end-page: 381 ident: bib0190 article-title: Not all postmenopausal women on chronic steroid and estrogen treatment are osteoporotic: predictors of bone mineral density publication-title: Calcif Tissue Int contributor: fullname: Arnaud – volume: 373 start-page: 1253 year: 2009 end-page: 1263 ident: bib0285 article-title: Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial publication-title: Lancet contributor: fullname: Saag – volume: 6 start-page: 558 year: 2010 end-page: 562 ident: bib0320 article-title: Accuracy of patient-reported height loss and risk factors for height loss among postmenopausal women publication-title: CMAJ contributor: fullname: Pouchain – volume: 26 start-page: 35 year: 2011 end-page: 41 ident: bib0255 article-title: Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up publication-title: J Bone Miner Res contributor: fullname: Zhu – volume: 46 start-page: 564 year: 2010 end-page: 570 ident: bib0080 article-title: Glucocorticoids, osteocytes, and skeletal fragility: the role of bone vascularity publication-title: Bone contributor: fullname: Weinstein – volume: 46 start-page: 3115 year: 2002 end-page: 3120 ident: bib0030 article-title: Missed opportunities in physician management of glucocorticoid-induced osteoporosis? publication-title: Arthritis Rheum contributor: fullname: Ramsey-Goldman – volume: 23 start-page: 581 year: 2012 end-page: 587 ident: bib0165 article-title: Prevalence of vertebral fractures in patients with rheumatoid arthritis: revisiting the role of glucocorticoids publication-title: Osteoporos Int contributor: fullname: Briot – volume: 19 start-page: 893 year: 2004 end-page: 899 ident: bib0135 article-title: A meta-analysis of prior corticosteroid use and fracture risk publication-title: J Bone Miner Res contributor: fullname: Oden – volume: 68 start-page: 373 year: 2009 end-page: 376 ident: bib0125 article-title: Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss publication-title: Ann Rheum Dis contributor: fullname: Dijkgraaf – volume: 19 start-page: 385 year: 2008 end-page: 397 ident: bib0205 article-title: FRAX publication-title: Osteoporos Int contributor: fullname: Oden – volume: 14 start-page: 212 year: 2011 end-page: 219 ident: bib0215 article-title: Official Positions for FRAX publication-title: J Clin Densitom contributor: fullname: Adachi – volume: 18 start-page: 1319 year: 2007 ident: 10.1016/j.jbspin.2014.10.001_bib0085 article-title: Glucocorticoid-induced osteoporosis: pathophysiology and therapy publication-title: Osteoporos Int doi: 10.1007/s00198-007-0394-0 contributor: fullname: Canalis – volume: 336 start-page: 262 year: 2008 ident: 10.1016/j.jbspin.2014.10.001_bib0235 article-title: Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial publication-title: BMJ doi: 10.1136/bmj.39440.525752.BE contributor: fullname: Bolland – volume: 26 start-page: 35 year: 2011 ident: 10.1016/j.jbspin.2014.10.001_bib0255 article-title: Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up publication-title: J Bone Miner Res doi: 10.1002/jbmr.176 contributor: fullname: Lewis – volume: 67 start-page: 277 year: 2000 ident: 10.1016/j.jbspin.2014.10.001_bib0280 article-title: Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy publication-title: Calcif Tissue Int doi: 10.1007/s002230001146 contributor: fullname: Wallach – volume: 15 start-page: 993 year: 2000 ident: 10.1016/j.jbspin.2014.10.001_bib0130 article-title: Use of oral corticosteroids and risk of fractures publication-title: J Bone Miner Res doi: 10.1359/jbmr.2000.15.6.993 contributor: fullname: Van Staa – volume: 313 start-page: 344 year: 1996 ident: 10.1016/j.jbspin.2014.10.001_bib0005 article-title: Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross-sectional study publication-title: BMJ doi: 10.1136/bmj.313.7053.344 contributor: fullname: Walsh – volume: 25 start-page: 2195 year: 1998 ident: 10.1016/j.jbspin.2014.10.001_bib0035 article-title: Variations in physicians’ judgments about corticosteroid-induced osteoporosis by physician specialty publication-title: J Rheumatol contributor: fullname: Buckley – volume: 17 start-page: 290 year: 2006 ident: 10.1016/j.jbspin.2014.10.001_bib0325 article-title: The accuracy of historical height loss for the detection of vertebral fractures in postmenopausal women publication-title: Osteoporos Int doi: 10.1007/s00198-005-2017-y contributor: fullname: Siminoski – volume: 27 start-page: 789 year: 2012 ident: 10.1016/j.jbspin.2014.10.001_bib0155 article-title: Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study publication-title: J Bone Miner Res doi: 10.1002/jbmr.1489 contributor: fullname: Kim – volume: 23 start-page: 581 year: 2012 ident: 10.1016/j.jbspin.2014.10.001_bib0165 article-title: Prevalence of vertebral fractures in patients with rheumatoid arthritis: revisiting the role of glucocorticoids publication-title: Osteoporos Int doi: 10.1007/s00198-011-1584-3 contributor: fullname: Ghazi – volume: 44 start-page: 202 year: 2001 ident: 10.1016/j.jbspin.2014.10.001_bib0185 article-title: Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial publication-title: Arthritis Rheum doi: 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W contributor: fullname: Adachi – volume: 48 start-page: 3224 year: 2003 ident: 10.1016/j.jbspin.2014.10.001_bib0200 article-title: Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy publication-title: Arthritis Rheum doi: 10.1002/art.11283 contributor: fullname: Van Staa – volume: 94 start-page: 1671 year: 2009 ident: 10.1016/j.jbspin.2014.10.001_bib0170 article-title: Age dependence of early symptomatic vertebral fracture with high-dose glucocorticoid treatment for collagen vascular diseases publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2008-1578 contributor: fullname: Tatsuno – volume: 65 start-page: 1495 year: 2006 ident: 10.1016/j.jbspin.2014.10.001_bib0120 article-title: Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis publication-title: Ann Rheum Dis doi: 10.1136/ard.2005.044198 contributor: fullname: Vis – volume: 357 start-page: 2028 year: 2007 ident: 10.1016/j.jbspin.2014.10.001_bib0295 article-title: Teriparatide or alendronate in glucocorticoid-induced osteoporosis publication-title: N Engl J Med doi: 10.1056/NEJMoa071408 contributor: fullname: Saag – volume: 19 start-page: 385 year: 2008 ident: 10.1016/j.jbspin.2014.10.001_bib0205 article-title: FRAX® and the assessment of fracture probability in men and women from the UK publication-title: Osteoporos Int doi: 10.1007/s00198-007-0543-5 contributor: fullname: Kanis – volume: 19 start-page: 893 year: 2004 ident: 10.1016/j.jbspin.2014.10.001_bib0135 article-title: A meta-analysis of prior corticosteroid use and fracture risk publication-title: J Bone Miner Res doi: 10.1359/JBMR.040134 contributor: fullname: Kanis – volume: 261 start-page: 170 year: 2007 ident: 10.1016/j.jbspin.2014.10.001_bib0150 article-title: Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study publication-title: J Intern Med doi: 10.1111/j.1365-2796.2006.01754.x contributor: fullname: de Vries – volume: 57 start-page: 140 year: 2007 ident: 10.1016/j.jbspin.2014.10.001_bib0040 article-title: Barriers in the management of glucocorticoid-induced osteoporosis publication-title: Arthritis Rheum doi: 10.1002/art.22462 contributor: fullname: Guzman-Clark – volume: 46 start-page: 3115 year: 2002 ident: 10.1016/j.jbspin.2014.10.001_bib0030 article-title: Missed opportunities in physician management of glucocorticoid-induced osteoporosis? publication-title: Arthritis Rheum doi: 10.1002/art.10619 contributor: fullname: Ramsey-Goldman – volume: 24 start-page: 2483 year: 2013 ident: 10.1016/j.jbspin.2014.10.001_bib0160 article-title: Biologic disease-modifying anti-rheumatic drugs and the risk of non-vertebral osteoporotic fractures in patients with rheumatoid arthritis aged 50 years and over publication-title: Osteoporos Int doi: 10.1007/s00198-013-2321-x contributor: fullname: Roussy – volume: 50 start-page: 289 year: 2012 ident: 10.1016/j.jbspin.2014.10.001_bib0290 article-title: Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate publication-title: Bone doi: 10.1016/j.bone.2011.10.024 contributor: fullname: Sambrook – volume: 19 start-page: 437 year: 2008 ident: 10.1016/j.jbspin.2014.10.001_bib0310 article-title: Cost-effective osteoporosis treatment thresholds: the United States perspective publication-title: Osteoporos Int doi: 10.1007/s00198-007-0550-6 contributor: fullname: Tosteson – volume: 60 start-page: 3346 year: 2009 ident: 10.1016/j.jbspin.2014.10.001_bib0300 article-title: Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial publication-title: Arthritis Rheum doi: 10.1002/art.24879 contributor: fullname: Saag – volume: 18 start-page: 1429 year: 2007 ident: 10.1016/j.jbspin.2014.10.001_bib0050 article-title: Corticosteroid-induced osteoporosis prevention: longitudinal practice patterns in The Netherlands 2001–2005 publication-title: Osteoporos Int doi: 10.1007/s00198-007-0345-9 contributor: fullname: Duyvendak – volume: 15 start-page: 1006 year: 2000 ident: 10.1016/j.jbspin.2014.10.001_bib0105 article-title: Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study publication-title: J Bone Miner Res doi: 10.1359/jbmr.2000.15.6.1006 contributor: fullname: Reid – volume: 47 start-page: 169 year: 2010 ident: 10.1016/j.jbspin.2014.10.001_bib0335 article-title: Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies publication-title: Bone doi: 10.1016/j.bone.2010.05.019 contributor: fullname: Giusti – volume: 11 start-page: iii year: 2007 ident: 10.1016/j.jbspin.2014.10.001_bib0305 article-title: Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis publication-title: Health Technol Assess doi: 10.3310/hta11070 contributor: fullname: Kanis – volume: 13 start-page: 777 year: 2002 ident: 10.1016/j.jbspin.2014.10.001_bib0095 article-title: The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis publication-title: Osteoporos Int doi: 10.1007/s001980200108 contributor: fullname: van Staa – volume: 27 start-page: 2424 year: 2000 ident: 10.1016/j.jbspin.2014.10.001_bib0275 article-title: A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid-induced bone loss publication-title: J Rheumatol contributor: fullname: Adachi – volume: 27 start-page: 1506 year: 2000 ident: 10.1016/j.jbspin.2014.10.001_bib0010 article-title: A Canadian survey on the management of corticosteroid-induced osteoporosis by rheumatologists publication-title: J Rheumatol contributor: fullname: Soucy – volume: 54 start-page: 3104 year: 2006 ident: 10.1016/j.jbspin.2014.10.001_bib0195 article-title: Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis publication-title: Arthritis Rheum doi: 10.1002/art.22117 contributor: fullname: van Staa – volume: S77 start-page: A86 year: 2010 ident: 10.1016/j.jbspin.2014.10.001_bib0060 article-title: Évolution de la prise en charge de l’ostéoporose cortisonique au sein du réseau rhumatisme inflammatoire chronique du Nord-Pas-de-Calais entre 2007 et 2010 publication-title: Rev Rhum contributor: fullname: Wibaux – volume: 347 start-page: f6234 year: 2013 ident: 10.1016/j.jbspin.2014.10.001_bib0230 article-title: The effect of fall prevention exercise programmes on fall induced injuries in community dwelling older adults: systematic review and meta-analysis of randomised controlled trials publication-title: BMJ doi: 10.1136/bmj.f6234 contributor: fullname: El-Khoury – volume: 42 start-page: 2309 year: 1999 ident: 10.1016/j.jbspin.2014.10.001_bib0100 article-title: Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study publication-title: Arthritis Rheum doi: 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K contributor: fullname: Cohen – volume: 62 start-page: 1515 year: 2010 ident: 10.1016/j.jbspin.2014.10.001_bib0070 article-title: American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis publication-title: Arthritis Care Res (Hoboken) doi: 10.1002/acr.20295 contributor: fullname: Grossman – volume: 9 start-page: 2493 year: 2013 ident: 10.1016/j.jbspin.2014.10.001_bib0140 article-title: Influence of recency and duration of glucocorticoid use on bone mineral density and risk of fractures: population-based cohort study publication-title: Osteoporos Int doi: 10.1007/s00198-013-2352-3 contributor: fullname: Majumdar – volume: 46 start-page: 3136 year: 2002 ident: 10.1016/j.jbspin.2014.10.001_bib0045 article-title: Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice publication-title: Arthritis Rheum doi: 10.1002/art.10613 contributor: fullname: Solomon – volume: 2 start-page: CD001347 year: 2000 ident: 10.1016/j.jbspin.2014.10.001_bib0315 article-title: Bisphosphonates for steroid-induced osteoporosis publication-title: Cochrane Database Syst Rev contributor: fullname: Homik – volume: 14 start-page: 212 year: 2011 ident: 10.1016/j.jbspin.2014.10.001_bib0215 publication-title: J Clin Densitom doi: 10.1016/j.jocd.2011.05.014 contributor: fullname: Leib – volume: 23 start-page: 2257 year: 2012 ident: 10.1016/j.jbspin.2014.10.001_bib0075 article-title: A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis publication-title: Osteoporos Int doi: 10.1007/s00198-012-1958-1 contributor: fullname: Lekamwasam – volume: 98 start-page: 191 year: 2005 ident: 10.1016/j.jbspin.2014.10.001_bib0175 article-title: A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids publication-title: QJM doi: 10.1093/qjmed/hci029 contributor: fullname: Van Staa – volume: 40 start-page: 673 year: 2011 ident: 10.1016/j.jbspin.2014.10.001_bib0260 article-title: La vitamine D chez l’adulte : recommandations du GRIO publication-title: Presse Med doi: 10.1016/j.lpm.2011.04.001 contributor: fullname: Benhamou – volume: 6 start-page: 558 year: 2010 ident: 10.1016/j.jbspin.2014.10.001_bib0320 article-title: Accuracy of patient-reported height loss and risk factors for height loss among postmenopausal women publication-title: CMAJ doi: 10.1503/cmaj.090710 contributor: fullname: Briot – volume: 61 start-page: 377 year: 1997 ident: 10.1016/j.jbspin.2014.10.001_bib0190 article-title: Not all postmenopausal women on chronic steroid and estrogen treatment are osteoporotic: predictors of bone mineral density publication-title: Calcif Tissue Int doi: 10.1007/s002239900351 contributor: fullname: Thompson – volume: 27 start-page: 2222 year: 2000 ident: 10.1016/j.jbspin.2014.10.001_bib0115 article-title: Decreased bone mineral density during low dose glucocorticoid administration in a randomized, placebo-controlled trial publication-title: J Rheumatol contributor: fullname: McKenzie – volume: 119 start-page: 963 year: 1993 ident: 10.1016/j.jbspin.2014.10.001_bib0110 article-title: Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study publication-title: Ann Intern Med doi: 10.7326/0003-4819-119-10-199311150-00001 contributor: fullname: Laan – volume: 97 start-page: 85 year: 2012 ident: 10.1016/j.jbspin.2014.10.001_bib0065 article-title: Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2011-2036 contributor: fullname: Koetz – volume: 41 start-page: 595 year: 2012 ident: 10.1016/j.jbspin.2014.10.001_bib0090 article-title: Glucocorticoid-induced osteoporosis and osteonecrosis publication-title: Endocrinol Metab Clin North Am doi: 10.1016/j.ecl.2012.04.004 contributor: fullname: Weinstein – volume: 68 start-page: 373 year: 2009 ident: 10.1016/j.jbspin.2014.10.001_bib0125 article-title: Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss publication-title: Ann Rheum Dis doi: 10.1136/ard.2008.091611 contributor: fullname: Wijbrandts – volume: 79 start-page: 304 year: 2012 ident: 10.1016/j.jbspin.2014.10.001_bib0225 article-title: 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis publication-title: Joint Bone Spine doi: 10.1016/j.jbspin.2012.02.014 contributor: fullname: Briot – volume: 23 start-page: 769 year: 2009 ident: 10.1016/j.jbspin.2014.10.001_bib0025 article-title: Secondary osteoporosis in patients with an osteoporotic fracture publication-title: Best Pract Res Clin Rheumatol doi: 10.1016/j.berh.2009.09.006 contributor: fullname: Kok – volume: 49 start-page: 493 year: 2011 ident: 10.1016/j.jbspin.2014.10.001_bib0020 article-title: Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW) publication-title: Bone doi: 10.1016/j.bone.2011.05.007 contributor: fullname: Díez-Pérez – year: 2013 ident: 10.1016/j.jbspin.2014.10.001_bib0330 article-title: Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research publication-title: J Bone Miner Res contributor: fullname: Shane – volume: 11 start-page: 92 year: 2008 ident: 10.1016/j.jbspin.2014.10.001_bib0220 article-title: Vertebral fracture assessment: the 2007 ISCD official positions publication-title: J Clin Densitom doi: 10.1016/j.jocd.2007.12.008 contributor: fullname: Schousboe – volume: 83 start-page: 1128 year: 1998 ident: 10.1016/j.jbspin.2014.10.001_bib0270 article-title: Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group publication-title: J Clin Endocrinol Metab doi: 10.1210/jcem.83.4.4742 contributor: fullname: Roux – volume: 50 start-page: 1982 year: 2011 ident: 10.1016/j.jbspin.2014.10.001_bib0015 article-title: Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/ker017 contributor: fullname: Fardet – volume: 339 start-page: 292 year: 1999 ident: 10.1016/j.jbspin.2014.10.001_bib0180 article-title: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis publication-title: N Engl J Med doi: 10.1056/NEJM199807303390502 contributor: fullname: Saag – volume: 63 start-page: 73 year: 2009 ident: 10.1016/j.jbspin.2014.10.001_bib0245 article-title: Use of calcium supplementation and the risk of coronary heart disease in 52–62-year-old women: the Kuopio Osteoporosis Risk Factor and Prevention Study publication-title: Maturitas doi: 10.1016/j.maturitas.2009.03.006 contributor: fullname: Pentti – volume: 24 start-page: 1891 year: 2013 ident: 10.1016/j.jbspin.2014.10.001_bib0055 article-title: Time trends for alendronate prescription practices in women with chronic obstructive pulmonary disease and women exposed to systemic glucocorticoids publication-title: Osteoporos Int doi: 10.1007/s00198-012-2220-6 contributor: fullname: Brask-Lindemann – volume: 39 start-page: 253 year: 2006 ident: 10.1016/j.jbspin.2014.10.001_bib0145 article-title: High prevalence of asymptomatic vertebral fractures in postmenopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study publication-title: Bone doi: 10.1016/j.bone.2006.02.005 contributor: fullname: Angeli – volume: 46 start-page: 564 year: 2010 ident: 10.1016/j.jbspin.2014.10.001_bib0080 article-title: Glucocorticoids, osteocytes, and skeletal fragility: the role of bone vascularity publication-title: Bone doi: 10.1016/j.bone.2009.06.030 contributor: fullname: Weinstein – volume: 22 start-page: 809 year: 2011 ident: 10.1016/j.jbspin.2014.10.001_bib0210 article-title: Guidance for the adjustment of FRAX® according to the dose of glucocorticoids publication-title: Osteoporos Int doi: 10.1007/s00198-010-1524-7 contributor: fullname: Kanis – volume: 373 start-page: 1253 year: 2009 ident: 10.1016/j.jbspin.2014.10.001_bib0285 article-title: Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(09)60250-6 contributor: fullname: Reid – volume: 341 start-page: c3691 year: 2010 ident: 10.1016/j.jbspin.2014.10.001_bib0240 article-title: Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis publication-title: BMJ doi: 10.1136/bmj.c3691 contributor: fullname: Bolland – volume: 342 start-page: d2040 year: 2011 ident: 10.1016/j.jbspin.2014.10.001_bib0250 article-title: Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis publication-title: BMJ doi: 10.1136/bmj.d2040 contributor: fullname: Bolland – volume: 303 start-page: 1815 year: 2010 ident: 10.1016/j.jbspin.2014.10.001_bib0265 article-title: Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial publication-title: JAMA doi: 10.1001/jama.2010.594 contributor: fullname: Sanders – volume: 364 start-page: 1728 year: 2011 ident: 10.1016/j.jbspin.2014.10.001_bib0340 article-title: Bisphosphonate use and atypical fractures of the femoral shaft publication-title: N Engl J Med doi: 10.1056/NEJMoa1010650 contributor: fullname: Schilcher |
| SSID | ssj0003256 |
| Score | 2.4051774 |
| Snippet | Abstract Objectives To update the recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis issued in 2003 by the French National... To update the recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis issued in 2003 by the French National Authority for Health... OBJECTIVESTo update the recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis issued in 2003 by the French National Authority... Objectives: To update the recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis issued in 2003 by the French National... |
| SourceID | proquest crossref pubmed elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 493 |
| SubjectTerms | Bisphosphonates Bone and Bones - drug effects Fracture Glucocorticoids Glucocorticoids - adverse effects Humans Internal Medicine Osteoporosis Osteoporosis - chemically induced Osteoporosis - physiopathology Osteoporosis - prevention & control Osteoporosis - therapy Recommendations Rheumatology Risk Factors Teriparatide |
| Title | 2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis |
| URI | https://www.clinicalkey.es/playcontent/1-s2.0-S1297319X14002206 https://dx.doi.org/10.1016/j.jbspin.2014.10.001 https://www.ncbi.nlm.nih.gov/pubmed/25455041 https://search.proquest.com/docview/1652413257 https://search.proquest.com/docview/1673385957 |
| Volume | 81 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBZ5QOml9J1HG1ToVVnLsiTrGELDtktyaBu6NyFZMjgQ29S71_72ztjy0lLSQk9GRmLkkTQznzUPQt5zzCNVKscqZxQr8qJkLssjk5mvua5z5TTGO1_fqOVt8Wkt13vkco6FQbfKJPsnmT5K6_Rmkbi56Jtm8YWPZZfMGiAChouqfXII6gjvag8vPq6WNzuBLPKxiCv2ZzhgjqAb3bzu_NA3mAiVF-ejmxd_SEM9ZIGOmujqKXmSTEh6Mc3yGdmL7XPy6Dpdkr8gEanQbY9YnnY1Rcx7fx9T9aSBdi0Fq4_2KXkTNF0b6M7jHIeMjuyAS4FC1wQGuB12QKAYENKBwd4NzfCS3F59-Hq5ZKmaAqskVxsmSq9N7UU0RoaylAB9g84qFRz-CnRaSKNqUxoPCquqNVgStRS1qkUAjR68EK_IQdu18YhQJcBScrEMPgB6c9LxUotgKp75XAQZjwmbOWj7KWmGnb3J7uzEcYu8wLfA8WOiZzbbOSAURFgc0nkaLLdDbjP7x5r_OvK3bWNBI_yD5rt5PS2cKLwmcW3stkBLSbxsBFn2tz4asL002Of1tBl2XwqQG2BfwU_-e26n5DG2Jq-ZN-Rg830b34Lts_FnZP_8Bz9LOxyfq8_fVj8BD_AETA |
| link.rule.ids | 314,780,784,4502,24116,27924,27925,45585,45679 |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Nb9UwDI_GkGAXND43GBAkrtlrmiZpjmhiesDeLmzSu0VJk0qdtLai7133t89u0wFCA4ljU0dJHcf2r7EdQj5yrCNVKscqZxQr8qJkLssjk5mvua5z5TTmO6_O1fKy-LqW6x1yMufCYFhl0v2TTh-1dWpZJG4u-qZZfOfjtUtmDRAB00XVA_KwkOD9glAf3_yM8xD5eIUrUjMkn_PnxiCvKz_0DZZB5cXxGOTF77NP9_mfox063SdPkgNJP01zfEp2YvuMPFqlI_LnJOIodNsjkqddTRHxXl_HdHfSQLuWgs9H-1S6CR5dG-hdvDl2GcPYAZXCCF0TGKB2WP9AMR2kA3e9G5rhBbk8_XxxsmTpLgVWSa42TJRem9qLaIwMZSkB-AadVSo4_BHotJBG1aY0HsxVVWvwI2opalWLAPY8eCFekt22a-MBoUqAn-RiGXwA7Oak46UWwVQ887kIMh4SNnPQ9lPJDDvHkl3ZieMWeYGtwPFDomc22zkdFBRYHNJuGiy3Q24z-8eK_9rzN6GxYA_-MeaHeT0t7Cc8JHFt7LYwlpJ41Aia7G80GpC9NEjzahKGuy8FwA2gr-Cv_3tu78nj5cXqzJ59Of_2huzhmyl-5ojsbn5s41vwgjb-3Sjlt0_aA4I |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=2014+update+of+recommendations+on+the+prevention+and+treatment+of+glucocorticoid-induced+osteoporosis&rft.jtitle=Joint%2C+bone%2C+spine+%3A+revue+du+rhumatisme&rft.au=Briot%2C+Karine&rft.au=Cortet%2C+Bernard&rft.au=Roux%2C+Christian&rft.au=Fardet%2C+Laurence&rft.date=2014-12-01&rft.pub=Elsevier+SAS&rft.issn=1297-319X&rft.volume=81&rft.issue=6&rft.spage=493&rft.epage=501&rft_id=info:doi/10.1016%2Fj.jbspin.2014.10.001&rft.externalDocID=S1297319X14002206 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F1297319X%2FS1297319X14X00060%2Fcov150h.gif |